RBR-29grfm
Not yet recruiting
Phase 2
Prospective, non-randomized, phase II study to assess the AIP and miR-34a expressions and the response to pasireotide LAR treatment in acromegaly patients
Faculdade de Medicina - Universidade Federal do Rio de Janeiro (UFRJ)0 sitesApril 25, 2016
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Acromegaly
- Sponsor
- Faculdade de Medicina - Universidade Federal do Rio de Janeiro (UFRJ)
- Status
- Not yet recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Age between 18 and 80 years; clinical indication of surgery as part of the treatment; laboratory and clinical confirmation of acromegaly; Signature of written informed consent.
Exclusion Criteria
- •Contraindications to surgery due to high surgical risk; Previous radiotherapy for pituitary adenoma treatment; Presence of AIP mutation; Medical treatment with somatostatin analogues, dopamine agonists or GH antagonist before surgery; Patients with compression of the optic chiasm causing any visual field defect that requires surgical intervention; Diabetic patients with poor glycaemic control as evidenced by HbA1c \>8%; Patients with symptomatic cholelithiasis and acute or chronic pancreatitis; Patients with risk factors for torsade de pointes, i.e. patients with a baseline QTcF \>450 ms in males, and \>460 ms in females; Hypokalaemia, hypomagnesaemia, uncontrolled hypothyroidism, family history of long QT syndrome or concomitant medications with known risk of Torsades de pointes (TdP); Patients who have congestive heart failure (NYHA Class III or IV), unstable angina, sustained ventricular tachycardia, clinically significant bradycardia, advanced heart block, history of acute myocardial infarct less than one year prior to study entry or clinically significant impairment in cardiovascular function; Concomitant disease(s) that could prolong the QT interval such as autonomic neuropathy (caused by diabetes or Parkinson’s disease), HIV, cirrhosis, uncontrolled hypothyroidism or cardiac failure; Patients with liver disease such as cirrhosis, chronic active hepatitis, or chronic persistent hepatitis, or patients with ALT/AST \> 2\.0 X ULN, serum bilirubin \>2\.0 X ULN; Presence of Hepatitis B surface antigen (HbsAg) or Hepatitis C antibody test (anti\-HCV); Patients with serum creatinine \>2\.0 X ULN; Patients with white blood cells \<3 X 109/L; Hb 90% \< LLN; Platelets \<100 X 109/L; Patients with active malignant disease in the last five years (with the exception of basocelular carcinoma or in situ cervix carcinoma); Patients with the presence of active or suspected acute or chronic uncontrolled infection; Patients who have undergone major surgery/surgical therapy for any cause within 4 weeks prior screening; Patients with abnormal coagulation (PT and/or APTT elevated by 30% above normal limits) or patients receiving anticoagulants that affect PT (prothrombin time) or APTT (activated partial thromboplastin time); History of syncope or family history of idiopathic sudden death; History of immunocompromise, including a positive HIV test result (ELISA and Western blot); known hypersensibility to somatostatin analogs or any other component of pasireotide; Sexually active males unless they use a condom during intercourse while taking drug and for 3 months following last dose of pasireotide and should not father a child in this period. A condom is required to be used also by vasectomized men in order to prevent delivery of the drug via seminal fluid; Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test; Women of child\-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during dosing and 3 months following last dose of pasireotide. Highly effective contraception methods include: abstinence (when this is in line with the preferred and usual lifestyle of the subject. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post\-ovulation methods) and withdrawal are not acceptable methods of contraception; Female sterilizati
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 2
A prospective non-randomized phase II study to assess the efficacy of unrelated cord blood transplantation for adult unfavorable hematological malignancies (C-SHOT 0601)Patients with acute myeloid leukemia/acute lymphocytic leukemia/myelodysplastic syndrome/chronic myelomonocytic leukemia categorized as high risk groupJPRN-UMIN000000600agoya Blood and Marrow Transplantation Group60
Completed
Phase 2
A prospective non-randomised phase II study to assess the safety and efficacy of melphalan combined with fludarabine as a reduced conditioning regimen for unrelated bone marrow transplantation for hematological malignancies (C-SHOT 0505)JPRN-C000000457agoya Blood and Marrow Transplantation Group54
Active, not recruiting
Not Applicable
A prospective randomized phase II study evaluating the monitoring of imatinib mesylate (Gliveec®) plasmatic through level in patients newly diagnosed with chronic phase chronic myelogenous leukaemia (CP-CML). - OPTIM IMATINIBChronic Phase Chronic myelogenous leukemia (CP CML)EUCTR2010-019568-35-FRCH VERSAILLES
Active, not recruiting
Not Applicable
A randomized trial to identify markers for personalized treatment in patients treated with bevacizumab and paclitaxel for advanced breast cancerAdvanced breast cancerTherapeutic area: Diseases [C] - Cancer [C04]EUCTR2012-003743-30-SEKarolinska University Hospital
Active, not recruiting
Phase 1
A study to assess the schemas of retreatment with Lutathera® in patients with new progression of intestinal well-differentiated neuroendocrine tumor.EUCTR2021-001306-30-FRInstitut Régional du Cancer de Montpellier146